The present invention relates to novel use of
interferon epsilon and, more specifically, to a pharmaceutical composition for the prevention or treatment of diseases, comprising
interferon epsilon as an
active ingredient. The pharmaceutical composition has significantly improved activity in a slightly acidic environment compared to a neutral environment, and thus can be administered systemically without separate treatment such as targeting or masking for controlling
systemic toxicity, and therefore, can be effectively used for the treatment of related diseases.